Trial Profile
A Pilot Study of Erlotinib and Temsirolimus in Patients with Advanced Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 23 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 14 Jun 2011 New trial record